Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 12;15(20):4957.
doi: 10.3390/cancers15204957.

Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers

Jiaxuan Xu  1 , Xiaoqing Dong  1 , David C S Huang  2   3 , Peipei Xu  1 , Quan Zhao  1 , Bing Chen  1
Affiliations
Review

Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers

Jiaxuan Xu et al. Cancers (Basel). .

Abstract

Targeting the intrinsic apoptotic pathway regulated by B-cell lymphoma-2 (BCL-2) antiapoptotic proteins can overcome the evasion of apoptosis in cancer cells. BCL-2 inhibitors have evolved into an important means of treating cancers by inducing tumor cell apoptosis. As the most extensively investigated BCL-2 inhibitor, venetoclax is highly selective for BCL-2 and can effectively inhibit tumor survival. Its emergence and development have significantly influenced the therapeutic landscape of hematological malignancies, especially in chronic lymphocytic leukemia and acute myeloid leukemia, in which it has been clearly incorporated into the recommended treatment regimens. In addition, the considerable efficacy of venetoclax in combination with other agents has been demonstrated in relapsed and refractory multiple myeloma and certain lymphomas. Although venetoclax plays a prominent antitumor role in preclinical experiments and clinical trials, large individual differences in treatment outcomes have been characterized in real-world patient populations, and reduced drug sensitivity will lead to disease recurrence or progression. The therapeutic efficacy may vary widely in patients with different molecular characteristics, and key genetic mutations potentially result in differential sensitivities to venetoclax. The identification and validation of more novel biomarkers are required to accurately predict the effectiveness of BCL-2 inhibition therapy. Furthermore, we summarize the recent research progress relating to the use of BCL-2 inhibitors in solid tumor treatment and demonstrate that a wealth of preclinical models have shown promising results through combination therapies. The applications of venetoclax in solid tumors warrant further clinical investigation to define its prospects.

Keywords: BCL-2 inhibitor; cancers; combination therapy; genetic mutations; venetoclax.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Figures were partly created with BioRender.com (accessed on 11 June 2023).

Figures

Figure 1
Figure 1
Chemical structures of commonly used BCL-2 inhibitors.
Figure 2
Figure 2
The process of cell-intrinsic apoptosis and action mechanisms of BCL-2 inhibitors.
See this image and copyright information in PMC

References

    1. Ashkenazi A., Fairbrother W.J., Leverson J.D., Souers A.J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discov. 2017;16:273–284. doi: 10.1038/nrd.2016.253. - DOI - PubMed
    1. Diepstraten S.T., Anderson M.A., Czabotar P.E., Lessene G., Strasser A., Kelly G.L. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat. Rev. Cancer. 2021;22:45–64. doi: 10.1038/s41568-021-00407-4. - DOI - PubMed
    1. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681. doi: 10.1038/nature03579. - DOI - PubMed
    1. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Investig. 2007;117:112–121. doi: 10.1172/JCI28281. - DOI - PMC - PubMed
    1. Del Gaizo Moore V., Schlis K.D., Sallan S.E., Armstrong S.A., Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111:2300–2309. doi: 10.1182/blood-2007-06-098012. - DOI - PMC - PubMed